刘慧

• 1:暨南大学附属第一医院药学部

摘要(Abstract)：

幽门螺杆菌(H.pylori)一种革兰阴性杆菌,可引起多种胃肠道疾病,主要定植在胃部。近年来在根除幽门螺杆菌治疗中抗生素耐药、根除率降低、不良反应增加等问题日渐凸显。益生菌(probiotics)制剂可提高幽门螺杆菌根除率、平衡胃肠道菌群和减少不良反应的作用逐渐受到关注。本文通过文献回顾,对近年来益生菌用于根除幽门螺杆菌治疗方案的研究进展进行综述。

关键词(KeyWords)： 幽门螺杆菌;益生菌;抗生素耐药

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘慧

参考文献(References)：

• [1]Lai CH,Kuo CH,Chen PY,et al.Association of antibiotic resistance and higher internalization activity in resistant Helicobacter pylori isolates[J].J Antimicrob Chemother,2006,57(3):466-471.
• [2]许飞利,李志刚,付萍,等.益生菌生理作用的最新进展[J].卫生研究,2011,40(2):277-278.
• [3]楚杰,郭刚,刘可春.布拉酵母菌防治肠道疾病的研究进展[J].中国微生态学杂志,2013(04):482-484.
• [4]Kang JH,Lee MS.In vitro inhibition of Helicobacter pylori by Enterococcus faecium GM-1[J].Can J Microbiol,2005,51(8):629-636.
• [5]Collado MC,Gonzalez A,Gonzalez R,et al.Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori[J].Int J Antimicrob Agents,2005,25(5):385-391.
• [6]Dahan S,Dalmasso G,Imbert V,et al.Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells[J].Infect Immun,2003,71(2):766-773.
• [7]Pinchuk IV,Bressollier P,Verneuil B,et al.In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics[J].Antimicrob Agents Chemother,2001,45(11):3156-3161.
• [8]Brzozowski T,Konturek PC,Mierzwa M,et al.Effect of probiotics and triple eradication therapy on the cyclooxygenase(COX)-2 expression,apoptosis,and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils[J].Helicobacter,2006,11(1):10-20.
• [9]张贺.布拉氏酵母菌联合三联疗法治疗儿童幽门螺杆菌感染疗效分析[J].中国民康医学,2013,25(1):38-40.
• [10]Zou J,Dong J,Yu X.Meta-analysis:Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication[J].Helicobacter,2009,14(5):97-107.
• [11]温建军,邱荣锋.双歧三联活菌制剂在根除幽门螺杆菌中疗效的临床研究[J].赣南医学院学报,2010,30(6):902-903.
• [12]蒋珍,范钟麟,王学红.益生菌联合四联疗法根治幽门螺杆菌相关性胃炎的临床研究[J].中国实用医刊,2013,40(9):61-62.
• [13]周晓娜,常丽丽,吴彦敏.益生菌联合三联疗法用于初治失败的幽门螺杆菌感染临床观察[J].临床合理用药杂志,2012,5(8):15-16.
• [14]林光勇,李菁,林晓晓,等.布拉酵母菌联合奥美拉唑阿莫西林克拉霉素治疗顽固性幽门螺杆菌感染的临床研究[J].中国微生态学杂志,2012(04):341-342.
• [15]Chapman CMC,Gibson GR,Rowland I.Health benefits of probiotics:are mixtures more effective than single strains[J].European Journal of Nutrition,2011,50(1):1-17.
• [16]Christensen HR,Fr Kiaer H,Pestka JJ.Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells[J].Journal of immunology(Baltimore,Md.:1950),2002,168(1):171.
• [17]胡慧珍,宋嘉,严杰,等.益生菌联合三联疗法根治幽门螺杆菌感染的临床观察[J].浙江临床医学,2011,13(6):617-619.
• [18]陈淑萍,王磊,余建奎.益生菌联合三联疗法根除幽门螺杆菌的临床研究[J].中华临床感染病杂志,2012(05):2.
• [19]Du YQ,Su T,Fan JG,et al.Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection[J].World J Gastroenterol,2012,18(43):6302-6307.
• [20]张灼阳,刘畅,郭晓奎.益生菌的安全性[J].微生物学报,2008(02):257-261.
• [21]刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2012(10).
• [22]陈勤安,龚小兵.益生菌在根除幽门螺杆菌感染中的临床价值[J].临床医学工程,2012,19(12):2152-2153.
• [23]刘志鹏,邹利权,游斌,等.微生态制剂对治疗幽门螺杆菌感染的影响[J].重庆医学,2009,38(5):542-543.
• [24]黄继英,曹海滨,时宝忆.培菲康联合标准三联疗法根除幽门螺杆菌疗效观察[J].上海医药,2008,29(12):552-554.
• [25]王维红,张振玉,徐亦君,等.益君康联合PPI三联疗法根除幽门螺杆菌的临床研究[J].中国实用医刊,2013,40(9):63-64.
• [26]何晨熙,刘改芳,朱新影,等.布拉酵母菌联合三联疗法根除幽门螺杆菌疗效研究[J].中国微生态学杂志,2014(03):306-309.
• [27]朱哲宇,郭晓东,闫志辉,等.布拉氏酵母菌联合PPI三联疗法治疗幽门螺杆菌性消化性溃疡的临床疗效观察[J].现代生物医学进展,2013(04):723-725.
• [28]高成城,谢睿,马天恒,等.布拉氏酵母菌联合标准三联疗法根除幽门螺杆菌的疗效研究[J].胃肠病学,2012,17(9):555-557.
• [29]邵付劼,鲁红利,侯顶.金双歧联合泮托拉唑、阿莫西林、甲硝唑治疗胃幽门螺杆菌的临床分析[J].健康必读(中旬刊),2012(9):243.